Barclays PLC Raises Position in Indivior PLC $INDV

Barclays PLC grew its holdings in shares of Indivior PLC (NASDAQ:INDV) by 1.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,124,553 shares of the company’s stock after acquiring an additional 25,493 shares during the period. Barclays PLC owned about 1.54% of Indivior worth $51,223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in Indivior by 1,122.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock worth $23,244,000 after acquiring an additional 1,447,939 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after purchasing an additional 1,299,425 shares in the last quarter. Rubric Capital Management LP boosted its position in shares of Indivior by 31.6% in the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after purchasing an additional 1,117,140 shares during the period. Jane Street Group LLC lifted its stake in shares of Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Indivior by 124.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company’s stock worth $21,977,000 after buying an additional 827,230 shares during the period. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on INDV. HC Wainwright lifted their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Northland Securities set a $50.00 price objective on shares of Indivior in a report on Tuesday, January 20th. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday, March 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Finally, Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.33.

Indivior Price Performance

Shares of NASDAQ INDV opened at $32.60 on Tuesday. The business’s 50 day moving average is $34.04 and its two-hundred day moving average is $30.45. Indivior PLC has a 1-year low of $8.64 and a 1-year high of $38.00. The stock has a market capitalization of $4.08 billion, a P/E ratio of 19.88 and a beta of 0.83.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. The business had revenue of $358.00 million during the quarter, compared to analyst estimates of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. As a group, equities research analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director David E. Wheadon purchased 1,771 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, with a total value of $62,675.69. Following the purchase, the director owned 14,395 shares in the company, valued at approximately $509,439.05. This trade represents a 14.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Keith Humphreys purchased 775 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director directly owned 5,802 shares in the company, valued at $205,332.78. The trade was a 15.42% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 4,871 shares of company stock valued at $172,385.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.